Innovation Portal

Under the umbrella of UConn’s Office of the Vice President for Research, Technology Commercialization Services works with innovators, entrepreneurs, investors, and industry partners to transform UConn discoveries into products, companies, and jobs that benefit society and fuel economic development.

Example:

general relativity

topology

homeostasis

polymers

geometric singularity detection

wireless communication systems

Health eSense

Shoreline Biome, LLC

azitra

technology incubation program

grant funding

innovation partnership building

cells

protein

genes

HIV

Research Unleashed

Over 100 world-class research centers and institutions

$260 million research expenditures in FY2017

Over 2000 full-time faculty conducting cutting-edge research

$1.5 billion Next Generation Connecticut state investment through 2024 on main campus in Storrs

880,000+ square feet of research space

500+ U.S. Patents granted based on UConn technologies

top 25 public research university

85+ startups supported by Technology Incubation Program

$864 million Bioscience Connecticut state investment in UConn Health research, academic, and clinical facilities

Technologies

Our online portfolio of inventions provides a searchable listing of technologies developed by UConn’s world-renowned faculty that are available for licensing or venture development. Search by keyword, topic, or faculty.

Expertise

At UConn, our faculty aren’t just internationally recognized experts in their fields. They are committed team members who can help propel a project forward. Learn more about our faculty experts and partnering opportunities.

Partner

As a research university, UConn offers distinct value to industry. By partnering with industry experts, entrepreneurs, investors, and public and private entities around the world, UConn is committed to supporting projects that benefit our state, nation, and the global community. Learn more about collaborating with our faculty, licensing our technologies, and leveraging our research expertise.

Startups

UConn’s venture development experts have helped launch dozens of companies related to UConn innovations.  From faculty- or student-led startups to ventures based on UConn technologies or companies in UConn’s Technology Incubation Program – we can help you move your idea forward.

twitterHAPPENING NOW: @ctnext Executive Director and @UConn alum Onyeka Obiocha discusses the intersection of climate chan… https://t.co/yfLdR5aNrIRT @uconnhealth: The @AFARorg and Hevolution Foundation have awarded Ming Xu, Ph.D. of the UConn Center on Aging (@UconnAging) and the Dep…RT @UConnCAHNR: An interdisciplinary group of researchers in @UConnCAHNR and @UConnEngineer have teamed up with other universities to estab…From @UConnPharmacy @CMichaelWhite2: https://t.co/oAyLfJNcr6In times of environmental upheaval, how do organisms respond? When entire species are wiped out, do surviving speci… https://t.co/Y3VOjDDpZEView All
×

Understanding the Physiological Role of KCNQ2 and KCNQ3 in Neonatal and Infantile Epilepsy Disorders

News Story
Ongoing/Future Research

Professor Anastasios (Tasso) Tzingounis has received a $1.7 million grant from the National Institute of Neurological Disorders and Stroke, the National Institute of Health and the Department of Health and Human Services to study the physiological role of two potassium channels, KCNQ2 and KCNQ3, in the brain.

Read more below.


Anna Zarra Aldrich, Office of the Vice President for Research

University of Connecticut physiology and neurobiology professor Anastasios Tzingounis has received a $1.7 million grant from the National Institute of Neurological Disorders and Stroke, the National Institute of Health and the Department of Health and Human Services to study the physiological role KCNQ2 and KCNQ3 potassium channels, ion channels implicated in neonatal and infantile epilepsy disorders, in the brain. Such work will provide an improved understanding of innate mechanisms that prevent aberrant activity in the brain and could lead to the development of novel anti-epileptic drugs.

The KCNQ2 and KCNQ3 genes code for potassium channels in the brain that transport positively-charged potassium ions which are necessary for the normal function of neurons. Dr. Tzingounis’s research group will conduct a series of studies to better understand the function and properties of KCNQ2/3 potassium channels in cell types that are crucial for shaping the activity of the brain and promote the development of neural networks necessary for mentation.

Dr. Tzingounis laboratory addresses questions related to molecular and cellular neuroscience using a combination of experimental approaches including mouse genetics, electrophysiology and microscopy. He received his PhD from the Vollum Institute at OHSU and did his postdoctoral work at UCSF.

In parallel to these studies, Dr. Tzingounis is also working with physiology and neurobiology professor Dr. Daniel Mulkey to study the link between KCNQ2 channel dysfunction and severe respiratory problems, issues observed with patients with KCNQ2 encephalopathy. NIH is also funding this new project:  1R01HL137094-01A1.

“KCNQ2/3 Channels and Interneuron Physiology” is NIH project: 1R01NS101596-01A1

(Photo by Bri Diaz, UConn College of Liberal Arts and Sciences)